000			03189cam a2200421Mi 4500
001			on1314619846
003			OCoLC
005			20240726104850.0
008			220507s2022 si o ||| 0 eng d
040			_aEBLCP _beng _erda _cEBLCP _dDXU _dNT
066			_c(S
020			_a9789815039740
020			_a9815039741
050	0	4	_aRC280 _b.N366 2022
049			_aMAIN
100	1		_aMukherjee, Biswajit. _e1
245	1	0	_aNanotherapeutics for the Treatment of Hepatocellular Carcinoma
260			_aSingapore : _bBentham Science Publishers, _c(c)2022.
300			_a1 online resource (557 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
500			_aDescription based upon print version of record.
504			_a2
505	0	0	_aCover -- _tTitle -- _tCopyright -- _tEnd User License Agreement -- _tContents -- _tPreface -- _tList of Contributors -- _tHepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy -- _tBiswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1 -- _tINTRODUCTION -- _tCANCER AND ITS TYPES -- _tPrimary Liver Cancer -- _tHepatocellular Carcinoma (HCC) -- _tIntrahepatic Cholangiocarcinoma (Bile Duct Cancer) -- _tAngiosarcoma and Hemangiosarcoma -- _tHepatoblastoma -- _tSecondary Liver Cancer
505	0	0	_aSurgical Resection in Advanced HCC -- _tAnatomical Resection -- _tLaparoscopic Resection of The Liver -- _tSurgical Resection of Re-Occurring HCC -- _tLiver Transplantation -- _tAblation -- _tPalliative Treatment -- _tEmbolizing Therapies for HCC -- _tTransarterial Chemoembolization (TACE) -- _tRadiotherapy -- _tSystemic Therapies of HCC -- _tFirst-line Therapy -- _tSecond-line Therapy -- _tMulti-Target Tyrosine Kinase Inhibitors -- _tImmune Checkpoint Inhibitor -- _tFUTURE PERSPECTIVES -- _tCONCLUSIONS -- _tCONSENT FOR PUBLICATION -- _tCONFLICT OF INTEREST -- _tACKNOWLEDGEMENT -- _tREFERENCES
500			_aHepatocellular Carcinoma and Therapeutic Challenges.
520	0		_aHepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics h.
530			_a2 _ub
650		0	_aLiver _xCancer _xTreatment.
650		0	_aNanomedicine.
655		1	_aElectronic Books.
856	4	0	_zClick to access digital title | log in using your CIU ID number and my.ciu.edu password. _uhttpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3199725&site=eds-live&custid=s3260518
942			_cOB _D _eEB _hRC. _m2022 _QOL _R _x _8NFIC _2LOC
994			_a92 _bNT
999			_c81024 _d81024
902			_a1 _bCynthia Snell _c1 _dCynthia Snell